Skip to content

Clinical efficacy study on the treatment of lumbar intervertebral disc herniation with cold-damp paralysis obstruction by adding Duhuo Gentiana Soup

Clinical efficacy study on the treatment of lumbar intervertebral disc herniation with cold-damp paralysis obstruction by adding Duhuo Gentiana Soup

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2024000287
Enrollment
Unknown
Registered
2024-08-22
Start date
2024-08-31
Completion date
Unknown
Last updated
2024-09-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

herniated lumbar disk

Interventions

Trial Group:Adding Duhuo Gentian Macrophyllae Soup + Basic Treatment

Sponsors

Wangjing Hospital, China Academy of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
Male
Age
30 Years to 70 Years

Inclusion criteria

Inclusion criteria: Inclusion Criteria 1) Meet the western medical diagnostic criteria of LDH, and meet the diagnostic criteria of cold-damp paralysis and obstruction in Chinese medicine; 2) Age between 30-70 years old, gender is not limited; (iii) Smooth communication, able to listen to the doctor's treatment, examination and scoring; (iv) Have not received lumbar spine invasive examination in the past 6 months, have not received lumbar spine surgery, and are not eligible for lumbar spine surgery. Patient; 5) Patients must not have undergone any other treatment of the same type within 7 days, and if they have, there must be a washout period of at least 7 days between treatments. (6) The patient gives informed consent to the study, participates voluntarily and signs the relevant informed consent form.

Exclusion criteria

Exclusion criteria: Exclusion Criteria 1) Symptoms that have been on for more than 3 consecutive months, seriously affecting normal life; 2) Combined with the upper central nervous system lesions or the presence of progressive aggravation of radicular nerve damage; 3) Patients with cauda equina syndrome who need surgery; (iv) Patients with allergy, or allergy to test drugs;6 (v) Patients with severe cardiac or cardiovascular diseases; (vi) Patients with severe cardiac or cardiovascular diseases Patients with severe heart, brain, liver, kidney, haematopoietic system and other diseases that require priority treatment. (6) Patients with mental illnesses who are unable to co-operate with the doctor's treatment; (vii) Patients who, according to the judgement of the researcher, have a low probability of being enrolled in the study, or who are likely to lose the study after enrolment due to various other reasons.

Design outcomes

Primary

MeasureTime frame
Visual Analogue Scale;

Secondary

MeasureTime frame
the Oswestry Disability Index;Criteria for assessing the efficacy of Chinese medicine;Japanese Orthopaedic Association Scores;Chinese Medicine Symptoms Score;lumbar spine mobility and straight leg raise test angle;

Countries

China

Contacts

Public ContactWang Shangquan

Wangjing Hospital of the Chinese Academy of Traditional Chinese Medicine

wsqdyf@163.com13901147122

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026